FXCM's 'Poison Pill' Is Just Another Empty News Release
Summary
•FXCM announced a Stockholder Rights Plan.
•Regardless of the plan, the arrangement with Leucadia with respect to timing and dispersal of sale proceeds remain unchanged.
•The plan is meaningless because no company will purchase FXCM on the open market when it can work out a deal directly with Leucadia and pay a much cheaper price.
This is my fourth article on FXCM Inc. (NYSE:FXCM) since the fallout from the Swiss Franc revaluation. I feel like I am beating a dead horse here but this morning's news release compelled me to write on FXCM once again. This article won't be so long and detailed as my others as I feel I have gone through every possible scenario for the company and it comes to the same conclusion. The stock is worth $1 to $2 based on a range of reasonable expectations of growth (or lack of it), customer debit balance collections, asset sales and ability to pay off the loan and when considering that any proceeds from a sale of the Newco will be subject to an allocation that heavily favors Leucadia (NYSE:LUK) and FXCM's note holders must be paid off before FXCM shareholders see a dime.